Introduction
Evidence-based medicine was presented as a new paradigm in the teaching and practice of medicine that stresses the examination of evidence from clinical research and discourages clinical decision-making based on intuition, unsystematic clinical experience and pathophysiologic rationale. 1 The development and implementation of evidence-based clinical practice guidelines (CPGs), one of the most promising and effective tools for improving the quality of care, was clearly linked to this movement.
2, 3 The main objectives of CPGs are to standardise procedures, reduce unjustified variations in clinical practice and change physician behaviour to promote the use of interventions supported by the best evidence available. [3] [4] [5] [6] [7] Several strategies have been described for the dissemination and implementation of CPGs once they have been developed. 4 The rapid expansion of computer usage in health care in recent years has allowed the development of computer-based CPGs. [8] [9] [10] [11] [12] [13] For instance, the region of Catalonia (Spain) has a computerised primary care system and the use of information technology in routine practice is set to increase. Indeed, the electronic medical record software has recently incorporated the electronic version of CPGs (e-CPGs) for the most common chronic disorders in the population (hypercholesterolaemia, diabetes mellitus type 2 and hypertension). [14] [15] [16] This electronic version includes the three key points that Grimshaw et al 4 defined for successful CPG dissemination and implementation procedures: easy access to the e-CPG, the use of reminders to guide the actions of healthcare professionals and finally, useful feedback to inform healthcare professionals about the appropriateness of their actions.
The main characteristic of the e-CPG system implemented by the Catalan Institute of Health is that it is linked to the electronic medical record system. This innovation allows the generation of individualised recommendations for the diagnosis, treatment, control and management of disorders considering patient characteristics. The e-CPG also includes information on drug safety (e.g. interactions, secondary effects) and can be updated whenever new drugs or diagnostic tests appear.
In addition, independently of e-CPG use, the contract for family practitioners (FPs) has been financially incentivised based on the degree of control for these chronic disorders. 17 All FPs are able to activate the software from a badge incorporated in the main page of the electronic medical record system.
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Keywords: electronic health records, physicians, practice guidelines as topic, primary care, primary health care have been conducted using a single disorder and selected FP samples. [8] [9] [10] [11] [12] We propose a study to ascertain the effect on FP habits of implementing the e-CPGs in a populationbased sample of records obtained from routinely collected general practice data. This population-based approach will allow us to include not only individuals with a wide range of severity of hypercholesterolaemia, diabetes mellitus type 2 and hypertension, but also those who do not meet all criteria for diagnosis but are at high risk of developing a disorder (suspected diagnosis). Finally, the sample size of the study will provide sufficient statistical power to estimate the effect of CPG implementation.
We hypothesise that a complex e-CPG integrated at several appropriate points in an electronic medical record (e.g. reminders and feedback) could increase FPs' access to e-CPG recommendations and achieve better results because complex assessments can be performed quickly. At the same time, point-of-care implementation will achieve consistent exposure to e-CPG recommendations and the evidence behind it, which should reduce variability in clinical practice regarding the control of clinical variables, and the diagnosis, treatment and management of hypercholesterolaemia, diabetes mellitus type 2 and hypertension.
Objectives
The main goal of this study is to assess the impact of the implementation of an e-CPG software for the control of clinical variables, and the diagnosis, treatment and management of hypercholesterolaemia, diabetes mellitus type 2 and hypertension.
Methods

Electronic clinical practice guidelines
The combination of a successful and flexible electronic medical record and rigorous, evidence-based e-CPGs may be ideal for introducing evidence-based practice into a wide variety of environments. The clinical guidelines for the prevention of hypercholesterolaemia, 14 diabetes mellitus type 2 15 and hypertension 16 to be used in the present study were developed between 2007 and 2011. To encourage the use of the newly available resources, official supporting materials were disseminated in routine seminars held in all primary care centres of the Catalan Institute of Health. 24 The incorporation of the e-CPG software throughout the medical record includes a screen that integrates the clinical information of patients with all preventive activities described in the CPG.
14- 16 The e-CPG is a two-level interactive software that guides the FPs' actions through pop-up windows with reminders. FPs are free to choose the level of interaction they want to work with. In the first level, the alert system recommends changes towards the diagnosis, treatment, control and management of each disorder (i.e. hypercholesterolaemia, diabetes mellitus type 2 and hypertension). In the second level, the FPs have access to the algorithms included in e-CPGs that point to the best evidence-based activities regarding diagnosis, treatment and follow-up in each particular case ( Figure 1) .
Additionally, the software assesses the FP's actions concerning: (1) the accuracy of diagnosis and pharmacological treatment; (2) the control of clinical variables; and (3) the appropriateness of follow-up undertaken, including tests performed. Each of the three items is colour-coded. The classification colours are white (patient values are correctly controlled), yellow (alerting FP to suspected diagnoses, such as a patient with systolic blood pressure 140 mmHg in a single measurement and without diagnosis of hypertension) and red (poorly controlled values, such as a diagnosis of diabetes mellitus type 2 and glycated haemoglobin > 7%). Two specific items referring to diagnosis and follow-up could also appear in red: (1) a missing primary or secondary prevention diagnosis for a patient whose values fulfil all the CPG criteria (e.g. a record with two total cholesterol determinations > 250 mg/dl and no diagnosis of hypercholesterolemia, or no secondary prevention diagnosis in the medical record of an individual with history of cardiovascular disease); (2) missing follow-up such as relevant tests for a particular diagnosis (e.g. microalbuminuria test) not performed within the last year in a patient with diabetes mellitus) ( Figure 1) . Tables 1 and 2 include the diagnoses recognised and treatments recommended by e-CPGs, respectively.
Study setting and selection of participants
The timeline of this project follows the e-CPG implementation process, which started in March 2010 with the hypercholesterolaemia guideline and finished in September 2011 with hypertension and diabetes guidelines.
We will analyse routinely collected data from electronic primary care registries corresponding to 279 primary care practices of the Catalan Institute of Health in Catalonia, with a total population of more than 2,800,000 patients aged 35-74 years (80% of the Catalan population). The volume of data guarantees population representativeness. 25 Eligible study participants are those aged 35-74 years at baseline, assigned to FPs working 36 hours or more per week. Those individuals who have changed their FP assignment during the study period will be excluded. The protocol . A cross-sectional study to describe the characteristics of the population-based sample before the e-CPGs implementation (January 2006 to December 2009). . A controlled before-and-after study with 1-year follow-up to ascertain the effect of e-CPGs implementation. 26 The patients will be divided into intervention and control groups according to the assigned FP and the number of times each FP accesses the e-CPGs, considered as a proxy of the use of these resources. Data will be collected in both groups contemporaneously, using similar methods before and after the intervention; therefore, all individuals are expected to experience similar secular trends or sudden changes. We will divide the sample in quartiles of FPs according to the number of patients whose record adheres to the e-CPGs. The intervention group will include the individuals assigned to FPs who use the e-CPGs system regularly (exposed, fourth quartile); the control group will include those assigned to FPs who do not use the CPGs regularly (non-exposed, first to third quartiles).
In June 2011, we analysed CPG adherence for hypercholesterolaemia at 1 year.
The CPG adherence analysis for diabetes and hypertension at 1 year and for hypercholesterolaemia at 2 years was performed in June 2012.
Outcome measures
Information about the benefits of this implementation strategy will be described regarding patients and FPs. First, outcomes will be expressed as: (1) control of clinical variables (e.g. cholesterol, glycated haemoglobin, blood pressure); (2) suspected and/or confirmed diagnoses; (3) proportions of patients with appropriate drug prescriptions; and (4) requests for tests (Tables 3-5) . All clinical variables will be measured following standard methodology by healthcare professionals (nurses and FPs) of the Catalan Institute of Health. Blood pressure is measured with a periodically calibrated sphygmomanometer with a cuff adapted to upper arm perimeter (young, adult, obese). Measurements are performed after a 5-minute rest with individuals seated. Two measurements were taken and the lower value was recorded in the electronic medical record. Blood is withdrawn after at least 8 hours fasting, with less than 60 seconds' duration. Lipid profile, glycaemia and glycated haemoglobin are determined following standard procedures at laboratories accredited by the Catalan Institute of Health with external quality control.
For pharmacological indicators, patients are considered as previously untreated for the disorder diagnosed if they have no medication prescriptions recorded in the 3 months prior to the beginning of the study.
Process-of-care variables are also considered study outcomes; all are aimed at assessing FP behaviour changes for the 12 months following the implementation, and at 24 months for the hypercholesterolaemia guidelines. The indicators of e-CPG usage are described in Table 6 .
Statistical analysis
Age-standardised prevalence will be determined for each goal described in Tables 2-4. Individuals will be categorised in 5-year age groups and a rough percentage or means calculated. This will be standardised by the direct method, with reference to the European population, for the purpose of the cross-sectional analysis. 27 These figures will be accompanied by the 95% confidence interval and stratified by sex.
To analyse the data of the controlled before-andafter design, categorical variables will be described as percentages; continuous variables with normal distribution will be described as mean and standard deviation. Variables in which normal distribution cannot be assumed will be described as median and interquartile range. Student's t-test for independent samples, MannWhitney U-test and chi-square tests will be used as appropriate to compare the clinical variables in the exposed and non-exposed groups. Between-groups analysis will be performed concerning the goals proposed in the follow-up: (1) suspected and confirmed diagnoses; (2) control of clinical variables; (3) requests for tests and (4) drug prescriptions adequacy; logistic regression models adjusted for potential confounders (i.e. variables significantly different between exposed and non-exposed groups in the bivariate analysis) will be used throughout.
Discussion
This study will evaluate the implementation of three eCPGs that started in 2010 and concluded in 2011. Population-based samples obtained from routinely collected general practice data will be used for this purpose. Indeed, notable information on quality of care that can be used for health service planning can be obtained from these data, with large potential use for research provided that three conditions are met. First, quality standards should be achieved; second, the databases should meet the information governance and research ethics guidelines; and finally, the data management system should ensure the traceability of data.
28,29
Evaluation of e-CPGs implementation
In recent years, many evidence-based CPGs have been developed for several disorders. 30 In 2001 the European Union funded the Appraisal of Guidelines Research & Evaluation (AGREE) Collaboration, which created the AGREE Instrument to provide a framework for assessing the quality of CPGs. 31 Despite these major investments by governments and scientific societies to create and evaluate evidence-based CPGs, the effect of CPG implementation on healthcare quality has been sparsely evaluated in populationbased samples. 9, [32] [33] [34] [35] [36] [37] The use of routinely collected data increases the sample representativeness and therefore the external validity of the study and provides an accurate description of such effect on FP attitudes. 28, 29, 38 Characteristics and limitations of the study Several limitations are inherent to outcomes research in the evaluation of CPG adherence. First, the observational nature of the study makes the choice of the study population and of the compared groups susceptible to selection bias. 39 However, the representativeness of our sample is guaranteed because it includes a broad sample of individuals aged 35-74 years from Catalonia (80% of the population). To avoid temporal trend bias we have chosen a controlled before-andafter design. All individuals are expected to experience similar secular trends or sudden changes because both groups are contemporaneous and the methods used before and after the intervention are similar. 26 In this study we will also evaluate the behaviour of FPs towards three common disorders in the population (hypercholesterolemia, diabetes and hypertension). All three disorders meet the four conditions that make them amenable to outcomes research: they have a precise diagnostic definition and a diagnostic test with high sensitivity and specificity, are reproducible among different individuals and locations, can be easily coded, and are common in the population. 39 Although e-CPGs may help FPs to improve the quality of health care, those with extensive experience in the field of cardiovascular risk factors will be less likely to rely upon these instruments. Similarly, financial incentives promoted by the Catalan Institute of Health to all FPs for reaching goals for population risk factor control may have an effect on the results. In addition, since we will do a follow-up of one year for adherence to e-CPG indications for diabetes mellitus type 2 and hypertension, some tests may not be completed during this period (e.g. electrocardiograms in individuals diagnosed with hypertension). In these cases a similar a priori effect will be expected in both groups of patients assigned to users and non-users of e-CPGs. Finally, the Hawthorne effect may alter our conclusions because FPs may improve or modify their behaviour simply because they are aware the records are being studied. However, the exhaustive, broad and diverse sample of FPs included in our study (> 3500) will minimise the potential bias and will make our results more relevant and generalisable. Additionally, socio-economic variables of the patient or community are not considered in this study. However, economic differences are minimised because the National Health Service in Spain ensures universal coverage of the population. The study also has unique strengths in addition to the representativeness of the patient population and the comprehensive access to FP data. All decisions in the implementation of e-CPGs in the Catalan Institute of Health were taken by expert consensus and the methodology used is replicable. Finally, the adherence to e-CPGs may not only reduce clinical practice variability but point-of-care access to the supporting evidence could also be an effective educational intervention for providers and patients.
Summary
This study has been designed to evaluate the implementation of three e-CPGs for the control of clinical variables, diagnosis, treatment and management of three major cardiovascular risk factors: hypercholesterolaemia, diabetes mellitus type 2 and hypertension. Several clinical implications may derive from the potential results. First, a new hypothesis regarding the strategies for implementation of e-CPGs will be generated. In addition, since individual data are available from every FP, we will be able to detect specific problems in CPG implementation. Second, this project will shed light on needs for discussion, education and use of evidence-based medicine to improve clinical practice of FPs. Finally, to know the effect of our actions on patients and on National Health System sustainability, assessment programmes such as the one described in this protocol should be evaluated. If a positive effect is observed from this analysis, such as an increase in the control of hypercholesterolemia, diabetes mellitus type 2 and hypertension, a reduction in non-recommended drugs and an efficient use of complementary tests, this model of e-CPGs could be extended to other regions in Spain or to other countries with electronic medical records systems. The first results of this study should be ready in late 2013. 
